Herein, we describe the development of a potential clinical anti-HtrA1 Fab for the treatment of AMD, as well as the discovery of an HtrA1-specific pharmacodynamic biomarker and its application to clinical studies. This evidence concerns the gene HTRA1 and age-related macular degeneration.